Filtered By:
Condition: Atrial Fibrillation
Countries: Canada Health
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 200 results found since Jan 2013.
Variation in bleeding risk estimates among online calculators: Cross-sectional study of apps used by and for patients with atrial fibrillation
CONCLUSION: Inconsistencies and a lack of precision were observed in annual risk estimates and risk stratification produced by Web and mobile bleeding risk calculators for patients with atrial fibrillation. Clinicians should refer to annual bleeding risks observed in major randomized controlled trials to inform risk estimates communicated to patients.PMID:35418403 | PMC:PMC9007121 | DOI:10.46747/cfp.6804e127
Source: Canadian Family Physician Medecin de Famille Canadien - April 14, 2022 Category: Primary Care Authors: Ryan Pelletier Jeff Nagge John-Michael Gamble Source Type: research
Association of Neighborhood-Level Material Deprivation With Atrial Fibrillation Care in a Single-Payer Health Care System: A Population-Based Cohort Study
CONCLUSIONS: Despite universal health care and prescription medication coverage, residents of more deprived neighborhoods were less likely to visit cardiologists or receive rhythm control interventions after AF diagnosis, even though they exhibited higher cardiovascular disease burden and higher risk of adverse outcomes.PMID:35678171 | DOI:10.1161/CIRCULATIONAHA.122.058949
Source: Circulation - June 9, 2022 Category: Cardiology Authors: Husam Abdel-Qadir Leo E Akioyamen Jiming Fang Andrea Pang Andrew C T Ha Cynthia A Jackevicius David A Alter Peter C Austin Clare L Atzema R Sacha Bhatia Gillian L Booth Sharon Johnston Irfan Dhalla Moira K Kapral Harlan M Krumholz Candace D McNaughton Ida Source Type: research
Starting anticoagulation for atrial fibrillation in the emergency department safely
Atrial fibrillation (AF) is a common morbidity, which is increasing in prevalence.1 AF predisposes patients to stroke while anticoagulation therapy reduces the stroke risk in this population. The proportion of patients with AF receiving oral anticoagulation is one of the pan-Canadian quality indicators set by the Canadian Cardiovascular Society.2 Our review of local ED practice identified that only 17% of patients with AF eligible for anticoagulation were being prescribed an anticoagulant.3 We implemented a simple ED pathway for initiating anticoagulation in patients with AF in four EDs. The pathway was available for emerg...
Source: Emergency Medicine Journal - October 21, 2022 Category: Emergency Medicine Authors: Kirwan, C., Ramsden, S., Carter, J., Tong, X. C., Huang, J., Clayton, N., McArthur, R., Kibria, A., de Wit, K. Tags: Research letter Source Type: research
Transcatheter vs Surgical Aortic Valve Replacement for Aortic Stenosis in Low-Intermediate Risk Patients: A Meta-analysis
Conclusions Although there was no difference in 30-day and late mortality, the rate of complications differed between TAVR and SAVR in the low-intermediate surgical risk population.
Source: Canadian Journal of Cardiology - August 25, 2017 Category: Cardiology Source Type: research
Chads2 score associated with atrial fibrillation but not predictive of stroke in adults with congenital heart disease
Publication date: October 2017 Source:Canadian Journal of Cardiology, Volume 33, Issue 10, Supplement Author(s): C. Tsui, D. Wan, J. Grewal, A. Barlow, M. Kiess, A. Krahn, D. Human, S. Chakrabarti, J. Sathananthan
Source: Canadian Journal of Cardiology - September 22, 2017 Category: Cardiology Source Type: research
Assessment and management of the Left Atrial Appendage Thrombus in Patients with Nonvalvular Atrial Fibrillation
Conclusion Integration of clinical, biomarker, and imaging risk factors can improve overall prediction for the presence of LAA thrombi, translating into improved patient selection for imaging. The gold standard for the diagnosis of LAA thrombi remains TEE, although ICE, CCT, and CMR are promising alternative modalities. When LAA thrombi are discovered, the treatment regimen remains variable, although DOACs may have similar efficacy to VKA. Future trials will help further elucidate DOAC use for the treatment of LAA thrombi.
Source: Canadian Journal of Cardiology - December 15, 2017 Category: Cardiology Source Type: research
Direct factor Xa inhibitors for long-term stroke prevention in atrial fibrillation: could the lower dose fit all?
Publication date: Available online 7 February 2018 Source:Canadian Journal of Cardiology Author(s): Thomas A. Mavrakanas, Manish M. Sood
Source: Canadian Journal of Cardiology - February 7, 2018 Category: Cardiology Source Type: research
Incident Atrial Fibrillation and Stroke in Patients with Atrial Flutter
Publication date: Available online 20 February 2018 Source:Canadian Journal of Cardiology Author(s): Jorge A. Wong, Jeff S. Healey
Source: Canadian Journal of Cardiology - February 20, 2018 Category: Cardiology Source Type: research
Sex Differences in the Incidence and Outcomes of Newly Diagnosed Atrial Fibrillation-Related Stroke
Publication date: April 2018 Source:Canadian Journal of Cardiology, Volume 34, Issue 4 Author(s): J.D. Edwards, A. Micieli, A.Y.X. Yu, J. Fang, D. Gladstone
Source: Canadian Journal of Cardiology - March 21, 2018 Category: Cardiology Source Type: research
A Review of the Use of Direct Oral Anticoagulant Use in Orthotopic Heart Transplantation Recipients
Over 60 years ago, the vitamin K antagonist (VKA) warfarin was approved and remained the only oral anticoagulation agent until recently [1]. Currently, within North America and Europe there are four DOACs available. Dabigatran, first approved in Europe and Canada in 2008, then in the United States of America in 2010, followed by rivaroxaban, apixaban, and most recently edoxaban. The introduction of direct oral anticoagulants (DOACs) has been a major advancement and these agents are the preferred to VKAs for many indications [2 –5], including stroke prevention in nonvalvular atrial fibrillation (NVAF), acute treatment and...
Source: Transplantation Reviews - April 16, 2018 Category: Transplant Surgery Authors: Rosaleen Boswell, Glen J. Pearson Tags: Review article Source Type: research
Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada
AbstractCanadian guidelines recommend non vitamin K antagonists (NOACs) in preference to vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF), but NOACs are more expensive than VKAs. Canada has a universal healthcare system that covers the cost of NOACs for select patient groups. Ability to pay for NOACs may influence their use. We reviewed medical charts of Hamilton General Hospital outpatients under the age of 65 with a new diagnosis of AF who were referred for initiation of OAC therapy. We contacted these patients by phone and asked them to complete a questionnaire regarding their...
Source: Journal of Thrombosis and Thrombolysis - June 5, 2018 Category: Hematology Source Type: research
